The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together

Inclusion Criteria:

• Healthy adult males & females ages 18-65;
• Body weight >50kg; BMI between 19-32;
• Signed and dated informed consent; QTc Interval <450 msec;

Exclusion Criteria:

• Resting blood pressure >140/90 mmHg or HR >100 at screening;
• History of drug allergy or other allergy which, in the opinion of the PI, contraindicates their participation;
• Positive urine drug, alcohol or serum pregnancy test at screening and prior to dosing;
• Positive HIV, Hepatitis B, C at screening; use of medications (except acetaminophen)or vitamins or herbal supplements within 7 days or 5 half lives prior to dosing and during study;
• history of urinary retention, gastric retention, and other sever gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma or who are at risk for these conditions;
• history of chronic constipation and/or regular laxative use; donation of more than 500mL of blood within 56 days prior to dosing;
• clinically relevant abnormality identified during screening process or any medical condition or circumstance making the subject unsuitable for participation based on the Investigators assessment